No photo of Victoria Meucci Villaflor

View Scopus Profile

Victoria Meucci Villaflor

  • 1282 Citations
20052022
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Training Experience

2001Residency, Rush University Medical Center
2004Fellowship, Rush University Medical Center

Education/Academic qualification

MD, Rush Medical College

… → 1998

Fingerprint Dive into the research topics where Victoria Meucci Villaflor is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Esophageal Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Head and Neck Neoplasms Medicine & Life Sciences
Chemoradiotherapy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
Induction Chemotherapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2017 2022

Prot #HCRN GI17-319/NU UNC19I02: A Single Arm, Multi-Center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-Line, Metastatic, HER2-Amplified Gastric and Esophageal Adenocarcinomas

Villaflor, V. M.

Hoosier Cancer Research Network, Inc., EMD Serono Research & Development Institute, Inc.

8/12/19 → 8/12/22

Project: Research project

Prot #GRN-1201-002: A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with PD-L1+ Non-Small Cell Lung Cancer

Villaflor, V. M.

ICON Clinical Research, LLC, BrightPath Biotherapeutics Co., Ltd.

8/1/18 → 8/1/21

Project: Research project

Prot #C-145-03: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Villaflor, V. M.

Chiltern International, Inc., Iovance Biotherapeutics, Inc.

2/23/18 → 2/23/21

Project: Research project

Prot #ML28897/PRO 02: MY PATHWAY: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, And Atezolizumab In Patients Who Have Advanced Solid Tumors With Mutations Or Gene Expression Abn

Villaflor, V. M.

Sarah Cannon Research Institute, Genentech, Inc.

11/27/17 → 3/31/20

Project: Research project

Prot #CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or

Villaflor, V. M.

Bristol-Myers Squibb Company

6/13/17 → 6/13/20

Project: Research project

Research Output 2005 2019

  • 1282 Citations
  • 40 Article
  • 8 Review article
  • 1 Chapter
  • 1 Comment/debate
4 Citations (Scopus)

Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti–PD-1/PD-L1 Therapy in Non–Small-Cell Lung Cancer

Chae, Y. K., Davis, A. A., Raparia, K., Agte, S., Pan, A., Mohindra, N. A., Villaflor, V. M. & Giles, F., Mar 1 2019, In : Clinical Lung Cancer. 20, 2, p. 88-96.e6

Research output: Contribution to journal › Article

Tumor Burden
Non-Small Cell Lung Carcinoma
DNA Repair
Ligands
Mutation

Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer

Chae, Y. K., Viveiros, P., Lopes, G., Sukhadia, B., Sheikh, M. M., Saravia, D., Florou, V., Sokol, E. S., Frampton, G. M., Chalmers, Z. R., Ali, S. M., Ross, J. S., Chang, S., Wang, S., Chiec, L., Rahbari, A., Mohindra, N. A., Villaflor, V. M., Shin, S. H., Oh, M. & 5 others, Anker, J., Park, L. C., Wang, V., Chuang, J. & Park, W., Jan 1 2019, (Accepted/In press) In : Journal of Thoracic Oncology.

Research output: Contribution to journal › Article

Frameshift Mutation
Lung Neoplasms
Tumor Burden
Atlases
Renal Cell Carcinoma

Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer

Chae, Y. K., Davis, A. A., Agte, S., Pan, A., Simon, N. I., Iams, W. T., Cruz, M. R., Tamragouri, K., Rhee, K., Mohindra, N. A., Villaflor, V. M., Park, W., Lopes, G. & Giles, F. J., Jun 1 2019, In : Oncologist. 24, 6, p. 820-828 9 p.

Research output: Contribution to journal › Article

Tumor Burden
Non-Small Cell Lung Carcinoma
DNA
Neoplasms
Programmed Cell Death 1 Receptor
8 Citations (Scopus)

Optima: A phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

Seiwert, T. Y., Foster, C. C., Blair, E. A., Karrison, T. G., Agrawal, N., Melotek, J. M., Portugal, L., Brisson, R. J., Dekker, A., Kochanny, S., Gooi, Z., Lingen, M. W., Villaflor, V. M., Ginat, D. T., Haraf, D. J. & Vokes, E. E., Feb 1 2019, In : Annals of Oncology. 30, 2, p. 297-302 6 p.

Research output: Contribution to journal › Article

Oropharyngeal Neoplasms
Chemoradiotherapy
Radiotherapy
Induction Chemotherapy
Clinical Trials
1 Citation (Scopus)

Complexity of Delivering Precision Medicine: Opportunities and Challenges

Davis, A. A., McKee, A. E., Kibbe, W. A. & Villaflor, V. M., May 23 2018, In : American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 38, p. 998-1007 10 p.

Research output: Contribution to journal › Review article

Precision Medicine
Information Dissemination
Clinical Trials
Neoplasms
Therapeutics